Lecanemab Sweeps Up Toxic Aβ Protofibrils, Catches Eyes of Trialists
In a comparison with aducanumab and gantenerumab, lecanemab mopped up protofibrils most efficiently; the antibody has been chosen for DIAN-TU and AHEAD 3-45 trials.
ALL NEWS
6066 RESULTS
Sort By:
- Most Recent
- Most Commented
More Tau Antibodies Bid Adieu; Semorinemab Keeps Foot in Door
At CTAD, scientists discussed whether a cognitive benefit on semorinemab was real, even as gosuranemab might have made people a bit worse. Other scientists are building an ambitious tau platform, including combination trials.
Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively?
Data shown at CTAD suggests the Aβ42/40 ratio falls in the blood before it does in the CSF, offering perhaps the earliest glimpse at the pathophysiology of Alzheimer's. Measuring that change prospectively might be a tall order.
Donanemab Phase 3 Puts Plasma p-Tau, Remote Assessments to the Test
At CTAD, all eyes were on the anti-amyloid antibody donanemab, which is before the FDA. Scientists showed how Phase 3 is enrolling, and how plasma tau enables wholly remote inclusion of people with plaques and tangles.
Clinical Trials on Alzheimer's Disease (CTAD) 2021 (Hybrid In-Person/Virtual)
Aduhelm Lowers Tau; Registry to Track Real-World Performance Donanemab Phase 3 Puts Plasma p-Tau, Remote Assessments to the Test Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively? More Tau Antibodies Bid Adieu; Semorinemab Keeps Foot in Door
Aduhelm Lowers Tau; Registry to Track Real-World Performance
While a death causes jitters, new blood phospho-tau data from Phase 3 trials strengthen the antibody’s claim to disease modification, and post-market studies seek evidence of benefit.
First GWAS of Primary Age-Related Tauopathy Digs Up JADE
The new gene JADE1 encodes an adaptor protein that sits in tangles and nonetheless appears neuroprotective. The study also turned up three AD and two PSP genes, suggesting PART overlaps with these conditions.
Vanquishing Brain Cancer: A New Mission for BACE inhibitors?
In cell culture and mouse models, verubecestat rallied tumor-promoting macrophages to eat glioma cells, slowing tumor growth.
When Abi3 Is a "No," Microglia Lose Their Get-Up-And-Go
In Alzheimer's mice without the AD risk gene Abi3, fewer microglia crowd around amyloid plaques. Cultured microglia without Abi3 appear stuck in a torpor, even though their phagocytosis mostly works.
Could Restoring Deep Sleep by Jolting the Brain Ward Off Alzheimer’s?
In mouse models, a sluggish thalamic reticular nucleus shortens slow-wave sleep. In one model, activating this brain area lengthened the mice's slumber while also reducing their plaque loads.
Do Lipids Lubricate ApoE's Part in Alzheimer Mechanisms?
At a recent conference, researchers presented more evidence tying the APOE4 allele to disrupted lipid metabolism. They linked this problem to Aβ production.
Slew of Studies Tie Health and Lifestyle Factors to Parkinson’s
Having a serious flu upped a person's odds of getting PD a decade later; a sedentary life dimmed prospects of living with PD; and cerebrovascular pathology implied more severe parkinsonism. Deaths due to PD have risen in the United States.
Doubling of Tau Seeds, Not Spread, Sets Pace of Tauopathy in Alzheimer's
A paper marrying math modeling with biological data proposes that, past Braak Stage III, tau aggregates double every five years in the neocortex. By this stage, they were already distributed throughout, de-emphasizing spread.
Aβ Clearance—The Untapped Potential of Astrocytes?
A combination of retinoic acid and the cholesterol drug gemfibrozil prompted astrocytes to ingest and degrade Aβ. Mice treated this way had fewer amyloid plaques and performed better on cognitive tests.
After Eating Tangle-Tainted Neurons, Microglia Spew Tau, Lose Appetite
Microglia regurgitate tau seeds. Then they retreat into a senescent torpor. In this state, they nonetheless pump out potentially hazardous metalloproteases.
Current Filters
No filters selected